Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone
Journal of Bone and Joint Surgery · 02.08.2023 · 105 (15) · 1145-1155
DOI: 10.2106/jbjs.22.01092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, online erschienen am 09.05.2023. Verfasst von Monica Florio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Research, Amgen, Thousand Oaks, California. Hauptthemen laut MEDLINE: Fracture Healing, Fractures, Bone. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Fracture repair involves the reactivation of developmental signaling cascades, including Wnt signaling that stimulates bone formation and bone regeneration. Rodent data indicate that dual inhibition of the Wnt signaling antagonists sclerostin and Dickkopf-1 (DKK1) increases callus bone volume and strength while increasing bone mass systemically.
Methods
We evaluated the effects of 16 weeks of subcutaneously administered carrier solution (vehicle, VEH), anti-sclerostin antibody (Scl-Ab), anti-DKK1 antibody (DKK1-Ab), or Scl-Ab plus DKK1-Ab combination therapy (COMBO) on ulnar osteotomy healing in nonhuman primates (cynomolgus monkeys; 20 to 22 per group).
Results
Scl-Ab and COMBO therapy increased systemic markers of bone formation versus VEH, with COMBO leading to synergistic increases versus Scl-Ab or DKK1-Ab monotherapies. The COMBO and Scl-Ab groups showed reduced serum markers of bone resorption versus VEH. The COMBO and DKK1-Ab groups exhibited greater callus bone mineral density (BMD), torsional stiffness, and torsional rigidity versus VEH. Lumbar vertebrae from the Scl-Ab and COMBO groups showed greater BMD and bone formation rate versus VEH, and the femoral mid-diaphysis of the Scl-Ab and COMBO groups showed greater periosteal and endocortical bone formation rates versus VEH.
Conclusions
DKK1-Ab increased BMD and strength at the ulnar osteotomy site, Scl-Ab increased bone formation and BMD at uninjured skeletal sites, and Scl-Ab plus DKK1-Ab combination therapy induced all of these effects, in some cases to a greater degree versus 1 or both monotherapies. These results in nonhuman primates suggest that DKK1 preferentially regulates bone healing while sclerostin preferentially regulates systemic bone mass. Clinical Relevance: Combination therapy with antibodies against sclerostin and DKK1 may offer a promising therapeutic strategy for both fracture treatment and fracture prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery Research, Amgen, Thousand Oaks, California.
- Phylon Pharma Services, Thousand Oaks, California.
- University of Michigan School of Dentistry, Ann Arbor, Michigan.
- Angitia Biopharmaceuticals, Guangzhou, Guangdong, People's Republic of China.
- Ascendis Pharma, Palo Alto, California.
ORCID-Profile: Monica Florio, Paul J Kostenuik, Marina Stolina, Franklin J Asuncion, Mario Grisanti, Hua Zhu Ke
Zitieren
APA
Florio, M., Kostenuik, P. J., Stolina, M., Asuncion, F. J., Grisanti, M., Ke, H. Z., & Ominsky, M. S. (2023). Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone. Journal of Bone and Joint Surgery, 105(15), 1145-1155. https://doi.org/10.2106/jbjs.22.01092
Vancouver
Florio M, Kostenuik PJ, Stolina M, Asuncion FJ, Grisanti M, Ke HZ, et al. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone. Journal of Bone and Joint Surgery. 2023;105(15):1145-1155. doi:10.2106/jbjs.22.01092
BibTeX
@article{Florio2023,
author = {Florio, Monica and Kostenuik, Paul J and Stolina, Marina and Asuncion, Franklin J and Grisanti, Mario and Ke, Hua Zhu and Ominsky, Michael S},
title = {Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone},
journal = {Journal of Bone and Joint Surgery},
year = {2023},
volume = {105},
number = {15},
pages = {1145--1155},
doi = {10.2106/jbjs.22.01092}
}
EUVIMED